Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.

about

Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.

Item

http://www.wikidata.org/entity/Q48267717

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Aqueous vascular endothelial g ...... -related macular degeneration.

@en

Aqueous vascular endothelial g ...... -related macular degeneration.

@nl

type

Item

label

Aqueous vascular endothelial g ...... -related macular degeneration.

@en

Aqueous vascular endothelial g ...... -related macular degeneration.

@nl

prefLabel

Aqueous vascular endothelial g ...... -related macular degeneration.

@en

Aqueous vascular endothelial g ...... -related macular degeneration.

@nl

P1476

Aqueous vascular endothelial g ...... e-related macular degeneration

@en

P2093

Masahito Ohji

http://www.w3.org/2001/XMLSchema#string

Osamu Sawada

http://www.w3.org/2001/XMLSchema#string

Xiying Wang

http://www.w3.org/2001/XMLSchema#string

Yoshitsugu Saishin

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Prevalence of age-related macular degeneration in the United States

Ranibizumab for neovascular age-related macular degeneration

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.

Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

P304

46-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CEO.13002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tomoko Sawada

P577

2017-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28621038

http://www.w3.org/2001/XMLSchema#string